<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="155354">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01077401</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00034586</org_study_id>
    <nct_id>NCT01077401</nct_id>
  </id_info>
  <brief_title>Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study</brief_title>
  <acronym>READ 3</acronym>
  <official_title>Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety, tolerability, bioactivity, and dose
      response of two different dosages (0.5 mg and 2.0 mg) of ranibizumab (RBZ) in patients with
      diabetic macular edema (DME).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3,6, 9 and 12 months</time_frame>
    <description>The primary outcome measures for safety and tolerability are the following:
The incidence and severity of systemic and ocular adverse events that are associated with repeated intravitreal injections of two doses of RBZ in subjects with DME such as cardiovascular events, intraocular reactions (inflammation), vitreous hemorrhage, retinal detachment, endophthalmitis (intraocular infection),increased intraocular pressure, and cataract formation, among others.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>3, 6, 9 and 12 months</time_frame>
    <description>Mean change in BCVA (ETDRS) at 4 meters in the study eye over time through month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anatomic Retinal changes</measure>
    <time_frame>3, 6, 9 and 12 months</time_frame>
    <description>Anatomic retinal changes in the study eye as assessed by color fundus photography,fluorescein angiography, and OCT, from Baseline to Month 6 and Month 12, including:
Extent of fluorescein leakage from CSME
Progression to proliferative diabetic retinopathy by ETDRS grade
Change in central retinal thickness, as assessed by OCT
Change in central retinal volume, as assessed by OCT.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Ranibizumab 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranibizumab 2.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.</description>
    <arm_group_label>Ranibizumab 0.5mg</arm_group_label>
    <other_name>lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.</description>
    <arm_group_label>Ranibizumab 2.0 mg</arm_group_label>
    <other_name>lucentis high-dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Signed informed consent and authorization of use and disclosure of protected health
        information

          -  Age ≥18 years

          -  Diagnosis of diabetes mellitus (type 1 or type 2)

          -  Serum HbA1c ≥ 5.5% within 12 months of randomization. Retinal thickening secondary to
             diabetes mellitus (diabetic macular edema) involving the center of the fovea

          -  Diagnosis must be confirmed by fluorescein angiography and OCT images

          -  Foveal thickness of ≥ 250 μm,

          -  Best corrected visual acuity score in the study eye of 20/40 to 20/320 inclusive
             (Snellen equivalents using the ETDRS protocol at a distance of 4 meters). The
             non-study eye must be ≥ 20 letters (approximate Snellen equivalent 20/400).

          -  In the opinion of the investigator, decreased vision in the study eye is due to
             foveal thickening from DME and not from other obvious causes of decreased vision If a
             female of childbearing potential, a negative pregnancy test and commitment to the use
             of at least two forms of effective contraception (birth control) for the duration of
             the study are necessary.

        Exclusion Criteria:

          -  Panretinal photocoagulation or macular photocoagulation within 3 months of study
             entry in the study eye

          -  Use of intraocular or periocular injection of steroids in the study eye (e.g.,
             triamcinolone) within 3 months of study entry

          -  Previous participation in a study and receipt of anti-angiogenic drugs (pegaptanib
             sodium, ranibizumab, bevacizumab, anecortave acetate, protein kinase C inhibitor,
             etc.) within 2 months of study entry

          -  Proliferative diabetic retinopathy in the study eye, with the exceptions of

          -  Inactive, fibrotic proliferative diabetic retinopathy that has regressed following
             panretinal laser photocoagulation OR

          -  Tufts of NVE less than one disc area with no vitreous hemorrhage

          -  Vitreomacular traction or epiretinal membrane in the study eye evident
             biomicroscopically or by OCT

          -  Structural damage to the center of the macula in the study eye likely to preclude
             improvement in visual acuity following the resolution of macular edema, including
             atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s),
             macular ischemia, or organized hard exudate plaque

          -  Ocular disorders in the study eye that may confound interpretation of study results,
             including retinal vascular occlusion, retinal detachment, macular hole, or choroidal
             neovascularization of any cause (e.g., AMD, ocular histoplasmosis, or pathologic
             myopia)

          -  Concurrent disease in the study eye that could compromise visual acuity or require
             medical or surgical intervention during the first 6-month study period

          -  Cataract surgery in the study eye within 3 months of study entry; Yttrium-Aluminum-
             Garnet (YAG) laser capsulotomy within 1 month of study entry; or any other
             intraocular surgery within 3 months preceding Day 0.

          -  History of vitreoretinal surgery in the study eye within 3 months of study entry

          -  Uncontrolled glaucoma (defined as intraocular pressure ≥30 mm Hg despite treatment
             with anti-glaucoma medications)

          -  Blood pressure exceeding 180/100 (sitting) during the screening period

          -  Uncontrolled diabetes mellitus, as evidenced by glycosylated hemoglobin (HbA1c) value
             &gt;13%

          -  Renal failure requiring dialysis or renal transplant

          -  Premenopausal women unwilling to commit to adequate contraception

          -  History of other diseases, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding giving reasonable suspicion of a disease or condition
             that contraindicates the use an investigational drug, might affect interpretation of
             the results of the study, or render the subject at high risk from treatment
             complications

          -  INR ≥ 3.0 (e.g. due to current treatment with warfarin). The use of aspirin or other
             anticoagulants is not an exclusion

          -  History of cerebral vascular accident, myocardial infarction, transient ischemic
             attacks within 3 months of study enrollment.

          -  Have a history of hypersensitivity to ranibizumab or any of its components

          -  Have the presence of active malignancy, including lymphoproliferative disorders.
             Subjects with a history of fully resolved basal or squamous cell skin cancer may be
             enrolled.

        Other

          -  Inability to comply with study or follow-up procedures

          -  Any other condition that the investigator believes would pose a significant hazard to
             the subject if the investigational therapy were initiated.

          -  Participation in another simultaneous medical investigation or trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana V Do, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Denton</last_name>
    <phone>410-502-7621</phone>
    <email>jdenton2@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Retina Vitreous Associates</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Boyer, MD</last_name>
      <phone>310-289-2478</phone>
      <email>vitdoc@aol.com</email>
    </contact>
    <investigator>
      <last_name>David Boyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>LaJolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kang Zhang, MD</last_name>
      <phone>858-246-0814</phone>
      <email>k5zhang@ad.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Kang Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Doheny Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dean Eliot, MD</last_name>
      <phone>323-442-6582</phone>
      <email>DEliot@doheny.org</email>
    </contact>
    <investigator>
      <last_name>Dean Eliot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Bay Retina Institute</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eugene Lit, MD</last_name>
      <phone>510-444-1600</phone>
      <email>esl@post.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Eugene Lit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Macula Institute</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ron Gallemore, MD</last_name>
      <phone>310-944-9393</phone>
      <email>retina2000@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ron Gallemore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Group of Florida</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Larry Halperin, MD</last_name>
      <phone>561-504-3666</phone>
      <email>lhalperin@mac.com</email>
    </contact>
    <investigator>
      <last_name>Larry Halperin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Institute of Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Bennett, MD</last_name>
      <phone>808-955-0255</phone>
      <email>deb@retinahawaii.com</email>
    </contact>
    <investigator>
      <last_name>Michael Bennett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois Retina Associates</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Pollack, MD</last_name>
    </contact>
    <investigator>
      <last_name>John Pollack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Symons, MD, PhD</last_name>
      <phone>913-588-6605</phone>
      <email>asymons@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Symons, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University Wilmer Eye Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Denton</last_name>
      <phone>410-502-7621</phone>
      <email>jdenton2@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Diana V Do, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Quan D Nguyen, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter A Campochiaro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eye Care Specialists</name>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <zip>18704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erik Kruger, MD</last_name>
      <phone>570-288-7405</phone>
      <email>efkrug@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Erik Kruger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Black Hills Eye Institute</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Prema Abraham, MD</last_name>
      <phone>605-341-9190</phone>
      <email>retina@bhrei.com</email>
    </contact>
    <investigator>
      <last_name>Prema Abraham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Callanan, MD</last_name>
      <phone>817-261-9625</phone>
      <email>dcallanan@texasretina.com</email>
    </contact>
    <investigator>
      <last_name>David Callanan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <lastchanged_date>March 29, 2010</lastchanged_date>
  <firstreceived_date>February 26, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Dr. Diana V. Do</name_title>
    <organization>Johns Hopkins University</organization>
  </responsible_party>
  <keyword>Diabetic</keyword>
  <keyword>edema</keyword>
  <keyword>DME</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
